NC-MZFY
NetraPharma
AI, clinical trial design, patient stratification
measurementoperating trials
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
AI, clinical trial design, patient stratification
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Notes from the call: Netramark is revolutionizing clinical trial design using explainable AI to identify patient subgroups that drive trial success or failure, addressing the 50-65% Phase 3 failure rate in pharmaceuticals. The company has secured FDA recognition through a Critical Path Innovation Meeting, validating its approach as distinct from traditional AI/ML methods, and is positioned as a global leader in precision medicine with $3M+ in contract backlog. Strategic Vision Netramark is enabling the "dawn of real precision medicine" by providing tools to stratify patient populations and identify who benefits from treatments, moving beyond decades of theoretical precision medicine discussions without practical implementation. Peer-Reviewed Validation: • 15+ publications in high-impact journals (Nature Digital Medicine, Archives, Frontiers in Pharmacology, impact factors ~15) • NIMH ketamine trial study: Netra AI identified 36 of 40 meaningful patient subgroups vs. DeepSeek find
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Do you wonder about AI and its influence in the medical field? Meet Dr. Joseph Geraci. A true Polymath with two PHD's in mathematics and physics, BSC Neorscience/Philosophy, Machine Learning expert, Oncology medicine researcher, co-founder and CSO/CTO of Netramark/Netra AI, Professor at multiple Univerisities. Groundbreaking research is happening under his guidance with the FDA and clinical trials for medicines to treat Cancer, Alzheimers and other hard to treat illnesses. Having worked with D ARPA, NASA and the FDA, Dr. G has extensive background and networks in multiple fields of study. Listen to Dr. Geraci's full epsiode by going to Talking To Horses the Podcast. #newpodcast #podcast #cancerresearch #machinelearning #AI #netramark #netraAI #Polymath #talkingtohorses #science #biology #podclip #podcastclips #decodingcancer #cancerdiscovery #cancertech #precisionhealth #cancerdiagnostics
The ‘International Investment Forum’ – (‘IIF’) provides information on investment trends and ideas, covering all aspects of various industries, from top executives and managers around the world.
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Join us for a Fireside Chat with George Achilleos, Chief Executive Officer of NetraMark Holdings Inc. (OTC: AINMF), with Senior Analyst M.Marin as they discuss the company's story and potential value to investors. https://scr.zacks.com/home/default.aspx https://www.netramark.com/ Subscribe to Zacks SCR for all the latest updates on small-cap and micro-cap stocks. #AINMF #NetraMark #AI #healthcare #medtech #clinicaltrials #ceo #smallcap #trading #otcmarket #smallcapstocks #smallcaps #investing _______________________________________________________________________ DISCLOSURE: The Zacks SCR analyst conducting this Chat hereby certifies that the views expressed accurately reflect the personal views of the analyst about the subject securities and issuer. Zacks SCR certifies that no part of any analyst’s compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this Chat. Zacks SCR believes the information used for the creation of th
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
The Market Online speaks with NetraMark Holdings CEO, George Achilleos as Netramark Announces Agreement with Worldwide Clinical Trials for Clinical Trial Design.
The ‘International Investment Forum’ – (‘IIF’) provides information on investment trends and ideas, covering all aspects of various industries, from top executives and managers around the world.
The ‘International Investment Forum’ – (‘IIF’) provides information on investment trends and ideas, covering all aspects of various industries, from top executives and managers around the world.
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Netramark's CEO George Achilleos and President Josh Spiegel join us to discuss their recent corporate update news release and provide a look at what to expect in the year ahead. Netramark Holdings Inc. trades on the CSE under the ticker AIAI. NetraMark was founded in 2016 by Dr. Joseph Geraci to address the current gaps in the pharmaceutical industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraAI is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover connections related to efficacy, toxicity and placebo response. NetraAI’s ability to uncover insights from small datasets is a key differentiator. Thinking about your wealth? Think MyWealth, think MyPlan, think MyPortfolio. Visit www.mywealthmanager.ca to learn more about our team and for ways to get in touch with us to help put you in the driver seat for your retirement plan. The views expressed in
NetraMark Holding's CEO, President, and Chief technology and Scientific Officer meet with the Townshend, Somani and Hunter Group to provide a corporate update. Netramark Holdings Inc. trades on the CSE under the ticker AIAI. NetraMark was founded in 2016 by Dr. Joseph Geraci to address the current gaps in the pharmaceutical industry. NetraMark developed proprietary algorithms that can change the way AI is used in this industry. NetraAI is a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal datasets to uncover connections related to efficacy, toxicity and placebo response. NetraAI’s ability to uncover insights from small datasets is a key differentiator. Thinking about your wealth? Think MyWealth, think MyPlan, think MyPortfolio (coming early 2021 to Townshend, Somani and Hunter Group clients). Visit www.mywealthmanager.ca to learn more about our team and for ways to get in touch with us to help put you in the driver seat
Host Jonathan Miller interviews CEO, George Achilleos. He describes the mission and growth of NetraMark. He also mentions several of the elements of the company who have kept the company on a great place.
230131 NetraMark Holdings Inc. (CSE:AIAI) is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “AIAI” having previously traded as Nurosene Health. This new name comes from NetraMark Corp, its wholly owned subsidiary acquired in October 2021. George Achilleos, CEO, stated: “This is reflective of the strategic shift that has been unfolding at our company and is a clear demonstration to our shareholders of our commitment to our corporate vision. It is our intent to be a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry. This is an important time for AI and there is a clear opportunity in the pharmaceutical industry, as outlined below.” From drug discovery through to FDA approval, developing a new medicine takes, on average, 10 to 15 years and costs approximately US$2.6 billion, with less than 12% of the candidate medicines successfully making it through the
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
NetraMark Holdings Inc. (AIAI) Opens the Market Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services SEDAR+ About SEDA … erme les marchés 2026-06-23 5:15 PM EDT Company Profile Aug 22, 2025 EDGAR Next Deadline Guide: Your Final Checklist " The EDGAR Next deadline is no longer a future concern—it is an immediate compliance requirement. Companies that fail to complete enrollment risk losing filing access at a critical time. " The EDGAR Next deadline is only weeks away. On September 15, 2025, the SEC will switch to its new system, and companies that haven’t completed enrollment risk being unable t
NetraMark Signs Contract With Pharmaceutical Company To Deliver Clinical Trial Insights Regarding Efficacy And Placebo Response | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
NetraMark Holdings Inc (AIAI) Stock, Price, News, Quotes, Forecast and Insights | MSN Money Popular AMC ▲ +14.29% BTC ▼ -0.08% CADUSD ▲ +0.07% ETH ▼ -0.48% BNB ▼ -1.44% GME ▲ +3.57% ADA ▼ -2.41% BB ▲ +10.33% TSLA ▲ +1.22% XRP ▼ -1.20% My watchlist BEGIN YOUR INVESTING JOURNEY Track and monitor your investments -- all in one place. Click on the icon to add stock to your watchlist. Suggested for you AMC Entertainment Holdings Inc AMC 2.16 +14.29% Bitcoin BTC 85,413.45 -0.08% CAD/USD US Dollar 0.70 +0.07% Ethereum ETH 2,232.03 -0.48% BNB BNB
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
NetraMark - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners T … ompany provides services such as product development, cloud and data solutions, application management, Salesforce and Relativity solutions, and low code and AI solutions. It was founded in 2010 and is based in New York, New York. Floworks Floworks specializes in artificial intelligence (AI) powered sales automation within the SaaS industry. It offers a platform that automates various aspects of the sales process, including lead generation, email communication, meeting schedu
%PDF-1.7 %���� 1 0 obj >/Metadata 899 0 R/ViewerPreferences 900 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���moA�ߓ� ��]vw�1iLl�F��_X_ �"� Z0�o����C�]�ml��;������,��������ӧp28΄�_�N�幆������h��%4S �V�Ӌ`B�M��w;�|x �g7���x����ѭ��ߚ�6 CQʘRF����3Ԁ�ynm0 W�72?b#�φ�{b��H� ���y��P7��UOF�� FW�-N��V�2ga4a����m�?� � ����sz���!��2#UE��c������0�����9� g�� ������\�ߌ�)�����y���A U� �׃'$gB��=����4����L�`0[N~.��E� ��b|�a�7�-g��X��� �( … �V��ONe �W����-�?w��2�n o�[��[�ݚ� E��F���Ro`�o�¸��a�C� ���Uw?��}e�WM��RFp�Q}/�ͷ�#�Z ��J_w��!��,5�^���B�:�Og�?�;y��كOf��s�̡�s�� �m�[��� 舋�����w|���~p_o��>y�sS�����c�a��(��ҟ�ۤ �`�˳��y�4��|�%��~�=D�s4�ۼ��� ������V��j�[4�L���7i(�T+����6����Rv�US��q��̙9 ��B%ot���8������"N�^���pqƷ�bL�#{�to�,�W��M^��&���O���8D�{ ���kO�����^6R����} x ŵnW��,ݳtOϾ�fՌf�I��Z,Y�-۲������Y�`���I !��/� a�^@� (ɻN�/$@����\�o�� 7$��W��#���n�{6LuWW�{N����9�Α��M�WIIJ��i��Z�1�
Careers | NetraMark AI Solutions TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact Careers Join the NetraMark Team! Browse our open job positions below to join a team dedicated to saving patient lives by transforming how drug development teams design and execute clinical trials. We are at the forefront of understanding why developed treatments work for some patients but not others and using our innovative AI approach … ients needing care options. Statistical Scientist View full job description. To apply, please email your resume and cover letter to [email protected] . We are seeking a Statistical Scientist to serve as a client-facing biostatistical advisor to craft guidance based on AI-generated statistical output and consult with clients on integration into protocol in accordance with FDA/EMA requirements. Precision AI uncovering the hidden patient attributes that power clinical trial su
Juvenescence raises $50 M in Series A financing HOME Pharma Generics Drug Discovery CMC & Manufacturing Clinical Trials New Drug Applications BioTech Biologics Stem Cells Vaccines Therapeutics MedTech Medical Devices Medical Diagnostic BioServices Contract Research Clinical Research Contract Manufacturing Pre Clinical Development Clinical Trial Phase Healthcare Digital Health COVID19 Artificial Intelligence Healthcare Logistics & Clinical Supply Chain Bio LAB Lab Products Lab Safety Lab Management Lab Design HER Health Cell & Gene Specials Bio interaction Premium Article Biopreneur … Medicine, a next-generation artificial intelligence company specialising in the application of deep learning to drug discovery and aging research; Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds; NetraPharma, a joint venture using artificial intelligence to improve clinical trial design; LyGenesis, a company with technology to use a patient’s own lymph nodes as bioreactors to grow funct … accept the terms & condition & Privacy policy Sign Up Forgot Password Email id Submit Close × Subscribe To Our Newsletter Email ID I accept the terms & condition & Privacy policy SUBSCRIBE! Close Guía completa para jugadores que buscan una plataforma moderna, segura y entretenida En un mercado digital cada vez más competitivo, los usuarios buscan experiencias que combinen simplicidad, variedad y transparencia. Al explorar opciones de entretenimiento en línea, resulta e … d-time tournaments, confirm that the rules detail how points are earned and how prize pools are distributed. To help you scan core offerings at a glance, review the table below. It summarizes categories that typically influence long-term satisfaction, including user experience, bonus structure, and support availability across devices. Category What to Look For Player Benefit Welcome Bonuses Transparent wagering, reasonable caps, clear eligible games Fair chance to convert bon … lobby, a clear cashier, and readable bet slips can be decisive for players who prize control and visibility. This is one reason experienced users continue to value jokaroom casino online access that feels smooth, uncluttered, and dependable across major browsers. For players comparing platforms, the verdict often rests on two pillars: trust and
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services | Financial Post Advertisement oop Story continues below This advertisement has not loaded yet, but your article continues below. Skip to Content Challenge your brain with PUZZMO's daily puzzles. Start playing >> Challenge your brain with PUZZMO's daily puzzles. Start playing >> Sections Search Search financialpost.com Perform search Share Share this Story : Financial Post Copy Link Email X Reddit LinkedIn Tumblr Subscribe for $0.99/week User My Account Subscribe for $0.99/week Sear
Premier American Uranium Expands and Further Defines Uranium Mineralization at Kaycee Project, Wyoming with Initial 2026 Drill Results - IRW-Press Skip to main content Skip to footer Home Newsroom Products About us Team Customers Contact FAQs Home Newsroom Products About us Team Customers Contact FAQs DE En Your trusted source for the latest news and press releases www.ir-world.com | [email protected] | +43 7242 211930-11 Premier American Uranium Expands and Further Defines Uranium Mineralization at Kaycee Project, Wyoming with Initial 2026 Drill Results Toronto, June 17, 2026 — Premier Amer … st.de Inverite Insights Inc. Investor-Magazin Incrementum Inflation Diversifier Fund infinitii ai Infinity Stone Ventures Corp. InnoCan Pharma Corporation Integral Metals Corp. Hyper Bit Technologies Ltd. Ideanomics, Inc. IDEX Metals Corp. Imagin Medical iMetal Resources Inc. Homerun Resources Inc. Horizon Petroleum Ltd. Humanoid Global Holdings Corp. Hybrid Power Solutions Inc Hydaway Digital Corp. Hello Pal International Inc. Heramed Limited Hertz Energy Inc. Hoenle AG GS M … required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from … required service and unblock content You need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from … required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data wi
AIAI Holdings (AIAI) Stock Price & Overview Skip to main content Log In Sign Up Home Watchlist Stocks Stock Screener Stock Exchanges Comparison Tool Earnings Calendar By Industry Stock Lists Top Analysts Top Stocks Corporate Actions IPOs Recent IPOs IPO Calendar IPO Statistics IPO News IPO Screener ETFs ETF Screener Comparison Tool New Launches ETF Providers News Trending Articles Technical Chart Fundamental Chart Market Movers Top Gainers Top Losers Most Active Premarket After Hours Market Heatmap Market Newsletter Stock Analysis Pro Tools Collapse AIAI Holdings Corporation (AIAI) AIAI Ho … le—we seek to improve the operating performance of our subsidiaries through the application of our proprietary AI. The AI that we will apply to the companies that we acquire will be licensed to us by Messier 42 LLC, or M42, a company controlled by our founder, John P Ro... [Read more] Industry Shell Companies Sector Financials Founded 2024 Employees 16 Stock Exchange NASDAQ Ticker Symbol AIAI Website https://aiaiholdings.com/ Full Company Profile News All Videos Press Press R
NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your searc … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum | Markets Insider Business Insider My Markets Watchlist Markets News Search Business Strategy Economy Finance Retail Advertising Careers Law Media Real Estate Small Business The Better Work Project Personal Finance Tech Science AI Enterprise Transportation Startups Innovation Markets Stocks Indices Commodities Crypto Currencies ETFs Lifestyle Entertainment Culture Travel Food Health Education Parenting Military & Defense Politics Reviews Home Kitchen Style Strea … also encouraged by the continued growth of our commercial pipeline, our active proposal activity, and the ongoing work to integrate NetraAI into the Worldwide Clinical Trials proposal build process. As sponsors face increasing pressure to design better trials, identify responder populations and extract clearer insights from complex clinical datasets, we believe NetraAI is well positioned to support the next generation of clinical development.” Second Quarter Operational High … zzata (FMP) to analyze the ROME Trial dataset. The collaboration is intended to apply NetraAI to a major precision oncology dataset, supporting the Company’s broader strategy of demonstrating the value of its technology in complex, high-impact clinical research settings. Presentation of AI-discovered treatment-responsive subgroups in the A4 Alzheimer’s Trial NetraMark unveiled AI-discovered treatment-responsive subgroups from the A4 Alzheimer’s Trial at the AD/PD Conference. … urance review to actively collaborating on integrating NetraAI into Worldwide’s proposal build process. Management believes this represents an important step toward embedding NetraAI earlier in the clinical trial planning and business development process, with the objective of enabling sponsors to evaluate NetraAI as part of trial design, enrichment and post-readout analytical strategies. Subsequent Events Following the Second Quarter Subsequent to the end of the second quart … urities legislation including statements regarding the anticipated development, application and integration of NetraMark’s NetraAI platform; the potential use of NetraAI to support clinical trial design, enrichment, analysis and interpretation; expectations regarding the recognition of revenue from contracted backlog as services are delivered; th
MAX Power closes $25 million strategic investment from Eric Sprott to accelerate commercial evaluation at Lawson - IRW-Press Skip to main content Skip to footer Home Newsroom Products About us Team Customers Contact FAQs Home Newsroom Products About us Team Customers Contact FAQs DE En Your trusted source for the latest news and press releases www.ir-world.com | [email protected] | +43 7242 211930-11 MAX Power closes $25 million strategic investment from Eric Sprott to accelerate commercial evaluation at Lawson This news release is not for distribution to U.S. newswire services for dissemina … owered Large Earth Model Integration (MAXX LEMI) Platform with potential global application for efficient targeting of Natural Hydrogen deposits; 7) General corporate purposes, including administrative and marketing expenses.   Private Placement Terms   Each Unit consisted of one common share in the capital of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Warrant ”). Each Warrant entitles Mr. Sprott to purchase one Common Sh … 21,000 hectares) of permits , plus an additional   5.7 million acres under application , covering prime exploration ground prospective for large-volume accumulations of Natural Hydrogen. MAX Power also holds a portfolio of properties in the United States and Canada focused on critical minerals. These properties are highlighted by a 2024 diamond drilling discovery at the Willcox Playa Lithium Project in southeast Arizona, 100%-owned by MAX Power’s U.S. subsidiary. MAX Pow … st.de Inverite Insights Inc. Investor-Magazin Incrementum Inflation Diversifier Fund infinitii ai Infinity Stone Ventures Corp. InnoCan Pharma Corporation Integral Metals Corp. Hyper Bit Technologies Ltd. Ideanomics, Inc. IDEX Metals Corp. Imagin Medical iMetal Resources Inc. Homerun Resources Inc. Horizon Petroleum Ltd. Humanoid Global Holdings Corp. Hybrid Power Solutions Inc Hydaway Digital Corp. Hello Pal International Inc. Heramed Limited Hertz Energy Inc. Hoenle AG GS M … required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from Turnstile to submit the form. Please note that doing so will share data wi
NetraMark taps Theocharous as fractional CMO | AINMF Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … ghts. According to the company, he will work closely with the executive team to apply AI outputs to decisions. Does NetraMark (AINMF) retain its previous Chief Medical Officer after this appointment? Yes. According to the company, outgoing CMO Dr. Larry Alphs will remain with NetraMark as an advisor to provide continuity and ongoing strategic input. Will Dr. Panteli Theocharous continue other roles while serving at NetraMark (AINMF)? Yes. According to the company, Dr. Theocha … ap Russell 2000® Index Jun 26, 2026 $PHUN Related Phunware Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Jun 26, 2026 $VG Related Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility Jun 26, 2026 $PKKFF Related Tenet Announces Refiling of Restated and Amended Q2-2025 Financial Statements Jun 26, 2026 $DCOY Related Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Jun 26, 2026 private placeme
Comparing Classical and Quantum Generative Learning Models for High-Fidelity Image Synthesis | Joseph Geraci | 12 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
NUROSENE APPOINTS SEASONED EXECUTIVE JOSH SPIEGEL AS PRESIDENT OF NETRAMARK Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. Advanced Search News in F … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
Portfolio Companies | Ontario Brain Institute Play A play symbol Twitter Logo for Twitter Twitter-x Logo for Twitter-x Facebook Logo for Facebook YouTube Logo for YouTube Instagram Logo for Instagram LinkedIn Logo for LinkedIn Search A magnifying glass Menu Three lines representing a menu Close An X Chevron An arrow pointing right Phone A ringing phone Email An envelope Toolkit A crossed screwdriver and wrench Guide A clipboard Report A piece of paper with writing on it Network A network of connected dots Research A microscope Business A pair of office towers Devices A hand holding a tablet co … rship opportunities with the OBI are welcome to share your company information. submit information © 2026 Ontario Brain Institute 1 Richmond Street West, Suite 400 Toronto, Ontario M5H 3W4 (647) 847-9000 1 (866) 637-6301 Accessibility for Ontarians with Disabilities Act (AODA) Compliance Stay Connected Contact Us Twitter profile Facebook profile Blog LinkedIn profile YouTube channel Instagram account Funding provided, in part, by the Government of Ontario
Contact NetraMark | AI Insights for Clinical Trial Design TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact Please fill out the form below to request a quote for a project, inquire about a collaboration, or simply say hello. Precision AI uncovering the hidden patient attributes that power clinical trial success. Quick Links Terms of Use Privacy Policy Contact Us 1655 Dupont St. #Suite 101 Toronto, ON M6P 3T1 info@net
NetraMark AI Appoints New Board Chairman at Annual Meeting | AINMF Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Sto … ap Russell 2000® Index Jun 26, 2026 $PHUN Related Phunware Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Jun 26, 2026 $VG Related Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility Jun 26, 2026 $PKKFF Related Tenet Announces Refiling of Restated and Amended Q2-2025 Financial Statements Jun 26, 2026 $DCOY Related Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Jun 26, 2026 private placeme
QCE22 Workshops Program ● IEEE Quantum Week Skip to content Home About About the Conference Conference Venue Participation Logistics In-Person Event with Virtual Component Media Center Contacts & Inquiries Conference Topics Key Deadlines Submission Deadlines Exhibitor Opportunities Financial Co-Sponsors Technical Co-Sponsors EDI Statement Code of Conduct COVID-19 QCE21 IEEE Quantum Authors Presenter’s Guide In-Person Event with Virtual Component Call for Contributions Conference Topics Submission Deadlines Key Deadlines Call for Tutorial Proposals Call for Workshop Proposals Call for … Panel Proposals Call for Posters Call for BoF Proposals EasyChair CFP EasyChair Submit Attend QCE22 Daily Friday Schedule, Floor Plans, Registration Hours Registration Desk Presenter’s Guide Fancy Program Brochure Program-at-a-Glance Participation Logistics Why Attend Conference Venue CCE22 In-Person Event with Virtual Component Program Synopsis EDI Statement Code of Conduct COVID-19 Program QCEE22 Daily Friday Onboarding Hubb Virtual Platform QCE22 Program Press Releas … Panel Proposals Call for Posters Call for BoF Proposals EasyChair CFP EasyChair Submit Attend QCE22 Daily Friday Schedule, Floor Plans, Registration Hours Registration Desk Presenter’s Guide Fancy Program Brochure Program-at-a-Glance Participation Logistics Why Attend Conference Venue CCE22 In-Person Event with Virtual Component Program Synopsis EDI Statement Code of Conduct COVID-19 Program QCEE22 Daily Friday Onboarding Hubb Virtual Platform QCE22 Program Press Releas … Intermediate Representations Alexander McCaskey: NVIDIA, USA Will Zeng: Unitary Fund, USA Sarah Kaiser: Unitary Fund, USA Yudong Cao: Zapata Computing, USA Bettina Heim: Microsoft, USA WKS13 — Integrating High-Performance Computing with Quantum Computing (WIPHQC) Sven Karlsson: Technical University of Denmark Laura Schulz: Leibniz Supercomputing Centre, Germany Martin Schulz: Technical University of Munich, Germany WKS14 — Real-Time Decoding for Fault-Tolerant Quantum Computi … 020 and 2021 Quantum Computing and Renewable Energy Workshops are encouraged to submit an application for updating us on their progress. We welcome submissions that focus on subjects such as quantum computing experimental results, algorithms development, and resource estimation. Furthermore, we welcome renewable energy and climate change research
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders - IRW-Press Skip to main content Skip to footer Home Newsroom Products About us Team Customers Contact FAQs Home Newsroom Products About us Team Customers Contact FAQs DE En Your trusted source for the latest news and press releases www.ir-world.com | [email protected] | +43 7242 211930-11 Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders Toronto, June 26, 2026 — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Urani … st.de Inverite Insights Inc. Investor-Magazin Incrementum Inflation Diversifier Fund infinitii ai Infinity Stone Ventures Corp. InnoCan Pharma Corporation Integral Metals Corp. Hyper Bit Technologies Ltd. Ideanomics, Inc. IDEX Metals Corp. Imagin Medical iMetal Resources Inc. Homerun Resources Inc. Horizon Petroleum Ltd. Humanoid Global Holdings Corp. Hybrid Power Solutions Inc Hydaway Digital Corp. Hello Pal International Inc. Heramed Limited Hertz Energy Inc. Hoenle AG GS M … required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from … required service and unblock content You need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from … required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers. More Information Unblock content Accept required service and unblock content You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data wi
Highlander Health Expands with Pedestal Health and Headwater Science Acquisitions | Highlander Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
NetraMark Delivers Transformational Quarter Of Execution --> Accessibility: Skip TopNav NetraMark Delivers Transformational Quarter Of Execution Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award Secured December 18, 2025 08:30 ET | Source: NetraMark Holdings Inc. NetraMark Holdings Inc. TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transformin … ed feedback on NetraAI—NetraMark’s explainable AI/ML platform—and discussed its application as an enrichment methodology in clinical trial design. The FDA provided feedback on NetraAI’s approach to pre-specified, α-controlled predictive enrichment and discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, consistent with FDA enrichment guidance. The FDA also discussed how NetraAI differs from complex adaptive designs, … Addiction and Mental Health (CAMH), was awarded a prestigious Ontario Research Fund – Research Excellence (ORF-RE) Award, recognizing innovative research partnerships in Ontario. Under this collaboration, NetraAI is being deployed within CAMH’s secure computing environment to analyze genetic and epigenetic data in schizophrenia and major depressive disorder. The work is focused on identifying explainable patient subpopulations and is expected to further strengthen NetraAI’s … er-reviewed publication and academic recognition, including our recent research award with CAMH. Completion of our onboarding with Worldwide Clinical Trials further expands our commercial reach and strengthens our route to market. Together, these milestones reinforce that our approach is both novel and increasingly aligned with the direction of modern clinical development. We remain focused on entering into new contracts, shortening sales cycles, and helping sponsors de-risk
NetraMark Partners With Worldwide Trials to Power AI-Driven Clinical Studies | AINMF Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI … ldwide's service offerings provides direct commercialization pathway Technology application across multiple trial phases indicates scalability Partnership expected to reduce trial costs and timelines for sponsors Negative Initial implementation to specific therapeutic areas Success of AI integration and adoption by sponsors yet to be proven News Market Reaction – AINMF +8.59% 1 alert +8.59% News Effect On the day this news was published, AINMF gained 8.59% , reflecting … ptimization of clinical trials by uncovering hidden patient subpopulations, the application of NetraMark's AI technology in Phase 2 and select Phase 3 clinical trials, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, Worldwide's ability to accelerate development timelines, refine patient stratification, reduce placebo response variability, and enhance overall trial power, the potential for NetraMark's partnership wit … ap Russell 2000® Index Jun 26, 2026 $PHUN Related Phunware Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Jun 26, 2026 $VG Related Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility Jun 26, 2026 $PKKFF Related Tenet Announces Refiling of Restated and Amended Q2-2025 Financial Statements Jun 26, 2026 $DCOY Related Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Jun 26, 2026 private placeme
NetraMark Announces Presentation at Sidoti Small Cap --> Accessibility: Skip TopNav NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026 June 09, 2026 07:00 ET | Source: NetraMark Holdings Inc. NetraMark Holdings Inc. TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a … Canadian securities legislation including statements regarding the anticipated application of NetraMark's NetraAI platform to identify specific patients driving the outcome of a clinical trial and to reveal who has a higher likelihood of response to a drug in clinical development, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use
%PDF-1.3 %��������� 3 0 obj > stream x�k� �q&�}~���C���܇%��H�"u#dY6�]-M�� �]����Of��d�uz����d�tuUV�++���k����Z����f�^oO��f�,���: ��f���-���k����������h���w�}Z|'�o[`�]�q���*`k��ۯM�,`�Ā{�� ֫�����w@o�Y�E!ǟ ���xX��;�[d���x�� ��i�> wˇ�i�=�χ���-?~�j@�Y��z� ���p�F�ñ9��/�[>�,^����_�wo=z��,� ?[>4��'����^������}u��YԼ��w����=zxw�l�?.�����g��fy�xU'˻w�-�����ճ�Gt�?��A ����� ����� �r�X���! �=�ӫ��X��l� �L���=u�p�A����?�������Ci�~�����ޫg�*���u�����p���˗�/�2t�%��y�j6���В.4�&�:��|�� ؘ-I� E0o�8����������~w���=���b �ſ�W����g��������ݏP- ����M��=ߙ� �U��x�c�^��B�� ��i
NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching … trial analytics, announces the presentation of new data demonstrating that the application of its NetraAI clinical solution to data sets of fewer than 400 patients can identify variables that predict efficacy and placebo responses in psychiatric clinical trials with high statistical significance. They also show that application of models based on these variables to independent patient populations correctly predicts efficacy and placebo responses, providing a novel approach t … ebo responders. The model also accurately identified 39/44 drug non-responders. Application of NetraAI to a failed, 332-patient Phase 3 anxiety trial identified 8 variables that were drivers of placebo response and 6 variables that were drivers of drug non-response. Importantly, this analysis showed that the drug response was very poor and similar to placebo in all but a small class of patients. Based on these findings, the efficacy of this drug is unlikely to be improve … he efficacy of this drug is unlikely to be improved in this patient population. Application of NetraAI to a 135-patient Phase 2a schizophrenia trial identified 4 variables driving placebo response and 3 variables driving drug non-response. Use of these variables in determining inclusion/exclusion criteria is expected to greatly improve the statistical significance for future trials of the therapy evaluated in the Phase 2a trial. Identifying efficacy variables for the use … nly 30% of the subpopulation identified by these variables was explainable, the application of these variables to a model of a larger trial is predicted to have a substantial impact on statistical significance — a reduction in p-value from 0.04 to 0.0019. "Traditional ML methods can be effective when they can be trained on large amounts of data a
Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial NPJ Digit Med . 2025 Dec 8;8(1):749. doi: 10.1038/s41746-025-02143-7. Authors Joseph Geraci 1 2 3 4 , Bessi Qorri 5 , Mike Tsay 1 , Christian Cumbaa 1 , Paul Leonczyk 1 , Larry Alphs 1 , Elizabeth D Ballard 6 , Carlos A Zarate J
Our Founding Story - Netramark TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact Our Founding Story Our Founding Story: How Uneven Treatment Patterns & Disease Definitions Inspired NetraMark’s Founding Authored & Edited By: Anna Falzon, Dr. Joseph Geraci, PhD Dr. Joseph Geraci, PhD Founder, CSO, & Chief Technology Officer at NetraMark Associate Professor in Molecular Medicine Queen’s U
NetraMark Appoints Dr. Panteli Theocharous As Fractional --> Accessibility: Skip TopNav NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI May 04, 2026 07:00 ET | Source: NetraMark Holdings Inc. NetraMark Holdings Inc. TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmace
NetraMark and Worldwide Clinical Trials Partner to Advance AI-Driven Precision in Global Clinical Trials 28 June, 2026 | Sunday Home Editorial 2026 Media Pack BioPharma Exclusive Subscribe Events Login BioPharma USFDA Drug Development Pharma Research Regulatory Clinical Trial Pharma Manufacturing Product Development and Pipeline Genomic and Personalized Medicine LifeSciences Biotech Biologics Clinical & Diagnostic Rare Diseases Therapeutics Lab Lab Products Lab Testing Contract Pharma Contract Research Contract Manufacturing Healthcare Digital Health Bio Innovation Public Health Cancer Tec … S Research Workflows 03 June, 2026 Editor Picks Acurex Biosciences Awarded ASAP Grant to Advance Novel Parkinson’s Disease Therapeutic Research 28 May, 2026 H. Lundbeck A/S Secures South Korea Approval for Eptinezumab to Prevent Migraine in Adults 27 May, 2026 Cornerstone Robotics Wins EU CE Mark for Sentire® Surgical System, Expanding Into European Markets 27 May, 2026 AGC Biologics Selected by Teikoku Seiyaku Co., Ltd. to Advance Microbial Manufacturing for KTP-001 in Lumba
Zacks Small Cap Research - Fireside Chat with George Achilleos, Chief Executive Officer of NetraMark Holdings Inc. Skip to main content Skip to main content --> --> Home Analyst Bios News Research Reports Companies by Analyst Steven Ralston, CFA David Bautz, PhD Ann Heffron, CFA, CPA Tom Kerr, CFA Michael Kim Brian Lantier, CFA M. Marin Brad Sorensen, CFA Lisa Thompson John Vandermosten, CFA Ronald Wortel, MBA, P. Eng. Companies by Name Research Notes Distribution Institutional Distribution Retail Distribution Social Media RSS Feeds Contact Subscribe Free Weekly Digest Zacks SCR Premium Watch … ials in X, Y, Z therapeutic area, and this is what we found, and now you should apply it to your trial, what we've done is taken a very, very novel approach. And that approach is, why don't we analyze the clinical trial data readouts that are coming from the pharmaceutical companies. And those are important to analyze because those are data sets that are very specific to the drug, one of the variables I talked about, and the patients that are getting the drug administered to … as to go forward to the FDA in particular with our technology and go through an application process with a very detailed documentation about what our technologies are, what the unique context of use of the technology is, et cetera. And if you can get through the CPIM, Critical Path Innovation Meeting application process, you get accepted into a meeting. And the reason you wanna be in the meeting, is because that is an opportunity to have a closed-door meeting with the FDA, wh … innovation and novelty to what you've built, I think you should go forward and apply to an ISTAND program or a varied amount of programs that could exist within the FDA. So as opposed to us just going forward and saying, we're gonna apply for an ISTAND or we're gonna do X and Y and Z, the better path we thought was to interact with the regulator, see if we would qualify to have a closed-door meeting with the regulator, so that we could actually work based on their guidance w … r timeframe is what we've been given. So, the good news, we've gone through the application process, we've been accepted for the Critical Path Innovation Meeting, and we're now in the process of scheduling that meeting. GA: And as I said, the expected benefits are clear feedback from the regulator with respect to how we fit, with respect to the c
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
14. IIF - NetraMark Holdings Inc. CEO George Achilleos | International Investment Forum (IIF) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Lin
George Achilleos, CEO NetraMark Holdings Inc. – International Investment Forum Home Insights Market Frontlines Documentaries Market Knowledge Market Trends Podcasts Virtual Conferences Registration Next Conferences Timetable – 20. IIF Timetable – 21. IIF Archive Timetable – 19. IIF Timetable – 18. IIF Timetable – 17. IIF Timetable – 16. IIF Timetable – 15. IIF Timetable – 14. IIF Timetable – 13. IIF Timetable – 12. IIF Timetable – 11. IIF Timetable – 10. IIF Timetable – 1. Hydrogen Day Timetable – 9. IIF Timetable – 8. IIF Timetable – 7. IIF Timetable – 6. IIF Timetable – 5. IIF Timetabl
Investors & Media - Netramark TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact CSE: AIAI | OTCQB: AINMF | FRA: 8TV Investor Presentation Download Now Press Releases September 15, 2023 – NetraMark Private Placement – Press Release Clarification September 11, 2023 – NetraMark Announces Private Placement Financing July 19, 2023 – Pharmaceutical Industry Veteran Joins NetraMark Advisory Board
NETRAMARK TO ATTEND AMERICAN SOCIETY OF CLINICAL ONCOLOGY CONFERENCE IN CHICAGO Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. Advanced Search News … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
#netramark #netraai #aacr #pancreaticcancer | NetraMark LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Polic
2025 Events | NetraMark AI Solutions TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact 2025 Events NetraMark will be present at the following Conferences & Events Explore shows we will be at in person, set a time to meet, or join our poster presentations. Submit the form below to request a copy of our scientific posters to be sent to you once available. More details on poster numbers, presenters, and presentation
#bio #sandiego #netramark #clinicaltrials #trialsuccess | NetraMark LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , P
NetraMark - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing list … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
NetraMark AI Boosts Pharmaceutical Clinical Trials with Precision Analytics | Toronto Stock Exchange posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu
The Quantum Insider You need to enable JavaScript to run this app.
Nurosene Health Inc. Signs Definitive Agreement to Acquire NetraMark, a Leading AI and Quantum Computing Company Accessibility Statement Skip Navigation Resources Investor Relations Journalists Webcasts Français --> Français my CNW Login Register Client Login PR Newswire Amplify™ Next Gen Communications Cloud Cision Communications Cloud® Sign Up Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and … arget="_self">my CNW Data Privacy Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform Next Gen Communications Cloud Cision Communications Cloud my CNW 877-269-7890 from 8 AM - 10 PM ET Terms of Use Information Security Policy Site Map Cookie Settings Accessibility Statement Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision co
Nurosene buys NetraMark, powers mental healthcare with AI | Canadian Lawyer CONTINUE TO SITE CONTINUE TO SITE NEWS Canada Features Opinion International PRACTICE AREAS ADR Criminal Family Immigration Insurance Intellectual property Labour and employment Medical malpractice Personal injury Privacy and data Real estate Tax Trusts and estates RANKINGS EVENTS RESOURCES Premium content Leaders network Legal education Legal technology People moves Practice management Professional regulation Multimedia Digital editions Careers White papers CL talk Editorial board SUBSCRIBE Newsletter CL+ CL+ Data Rep … nts and therapeutic formulations in collaboration with their proprietary mobile application." By 2028, the projected market size of global AI in healthcare will reach US$120.2 billion. Ranj Bath, Nurosene CEO, said in a press release , "The size of the market and projected growth of AI in healthcare, leaves no question for Nurosene and the acquisition of NetraMark. The technology NetraMark has developed will position Nurosene to be a key player in this sector.&rdquo … sent Preferences Terms of Use Terms & Conditions Digital Subscription Agreement Submit your move Copyright © 2026 KM Business Information Canada Ltd.
NetraMark lands new Phase 3 trial analytics contract | AINMF Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oi … ap Russell 2000® Index Jun 26, 2026 $PHUN Related Phunware Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Jun 26, 2026 $VG Related Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility Jun 26, 2026 $PKKFF Related Tenet Announces Refiling of Restated and Amended Q2-2025 Financial Statements Jun 26, 2026 $DCOY Related Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Jun 26, 2026 private placeme
NetraMark Announces Change To Board Of Directors --> Accessibility: Skip TopNav NetraMark Announces Change To Board Of Directors May 07, 2026 16:30 ET | Source: NetraMark Holdings Inc. NetraMark Holdings Inc. TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy has resigned from the Company’s Board of Directors, effective M
%PDF-1.3 %��������� 3 0 obj > stream x��ێ ����S�� �: �$�b0���� 42"� ���������9ر!���T��N��.����Y�j�1�����ֲ�j�R�wo��.�//^�����Ŷ���r�T�� ���n|9xݝ8�-�-�6y� r�����̣V4�8��M�vm�`u�1k ,w֔��yv�r{�|u# �����R��'>K���g떛���ͭ8����m�z����� �^>w�����k\݈�\}ݾ,|��U;����Dno_^��|���DY:�W�����w��7[X�3*��0*�˧�� � ����}��E}�� �N�����s�T�#&���z���*� |��>�A�\���yoM@��` �.�=��7?� DY�.��K��&wrd�(�h@n�H��&q�|���e����8Z�W?��ՍԊvRIk�I�`Wc��!R\��t0��G��P��y���*���L����ڒ 4�5�������H��m\CM�t���M�'~&�>$�����b3$i��p`��S� �_� �^�5^R^〴@�uR]}��kM KD�\nVu D�16���jS?g���3?9.H�.u�w�m��0`Pz��ZHϹ��Ǣ … �ݫ&?.� Xt1�}��Y���d�����6����n�����s ��굠[� g��C�9�;��s[,���6oy>�G���rfP VGh�C�.k�"�YV��7� >¢w��5: �5 jc�pT&�7���s�� ��(�� a;��� � u�������jܡA�Q�MqK������_tud ��b��斸��(= ��Z- ����/=�y\���y���au���ۅ��A� ��!�� �+�8:W����'�s��*:��Y�%� f�3(���ه�%eYύ|��n�����5����XRCS�`X7H Y.|���҅���5�(L�2��U��7��4㠇�3&n�a9͊A5`(?oJ~��b& o�d��Ph�����[y=5��nN�����2�Q.;"�6�ϿB� 9� *�D���ѱW]�j�!,�����B�э���id��{ $�����I��K־m���� �tPR�&�lg���;h1z&�E … �'wSM})��T]��T�16�jͫ��jr�#��ME;�T��-+�;D�s�ܼ1�t�#��� �TMs =r � ��9D��!rfp��IUD�����-���䛻eLy�~�/�z��� �} ޘ��M&Uc��j�5n�꼵�ōs�'>��q�=U �1���ŭ�p�QJ@vP���1������!r:E.?���_6>��7�V�K �w%�T���9�s[:x�9 r��r�3����q�^��&�$ \�X1펝��}ۤ�� ���8 ��G�+iR�o3 �=U�S�gǍ�ƥ葋F��.b�@��1������!r�D��Ɉ��Rkqr��'���R4�Ԫ���"��)��-_���V�R�㌜T�� "gBQ�"��� 7��S�I�xlߐ �}�m5����pR�3kR� kR�圓�i��D.2��vL����"r����oqz'U�s =r�J ��?����|���kޭ��i���u�ÿ�m��p����b��j}DZ�փ"r� ��O �zR
%PDF-1.3 %��������� 3 0 obj > stream xݽi� Ǒ��=E��RU�/") ��[�������ԇ ����� s���#"#*3�]�#d�����nn��_翝�u��/��o�= V��|��������]��������c~�������/���F����=+����A'���4���} ��}�n �C����f1�@k�� �3 ��c�j���-���y����~���c~����~�;���X w��lq�ܯ���qm���6���wo������~�X� ���£o�//��m��zG_FJ>���(�տ�4� �J�[o�M�S��.�w��r=�]�w���8����R��q�ͷt�|���j��7����f�o�m�_�7 �Q�Q���ۛ���Y�y^�m+�(%^�e��K����m�a���yX�����U�w]��:�/Z�6��;���z��&�w��ޫy�� ��~������o�FFؽZ�Ђ�qް{7;����������t ����º ��@���ςF��b��^r���I�ZA���� ��i��֙�6��}�M�t#����j�ѻ��\�{��^���͏�����O�wv� ����[���[�և��O�Jk�>�G�x��&U�UK+9���f
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY December 9, 2024 | 5 min read Twitter LinkedIn Facebook Email Print TORONTO , Dec. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier ar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NETRAMARK TO PRESENT NOVEL AI-BASED CLINICAL TRIAL TREATMENT SEPARATION TOOLS AT ISCTM ANNUAL MEETING - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NETRAMARK TO PRESENT NOVEL AI-BASED CLINICAL TRIAL TREATMENT SEPARATION TOOLS AT ISCTM ANNUAL MEETING February 18, 2025 | 5 min read Twitter LinkedIn Facebook Email Print TORONTO , Feb. 18, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV)&nb … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Ca … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES February 10, 2022 | 7 min read Twitter LinkedIn Facebook Email Print Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), is partnering, via its wholly owned subsidiar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset March 25, 2026 | 8 min read Twitter LinkedIn Facebook Email Print The collaboration aims to uncover clinically actionable patient subpopulations and biomarker … r of NetraMark. “We are pleased to collaborate with FMP on the ROME program and apply this methodology to potentially produce insights that can be communicated clearly to clinical stakeholders and those responsible for translating findings into trial design, regulatory strategy, and patient care.” The ROME Trial The ROME trial, reported in Nature Medicine , is a multicentre, randomized, open-label phase 2 study comparing tailored treatment to standard of care. The study evalu … Clinical Value of the Collaboration Through this collaboration, NetraMark will apply its proprietary NetraAI platform to analyze the ROME dataset and other oncology datasets made available by FMP, with the goal of uncovering clinically meaningful patient subpopulations and biomarker-anchored treatment patterns. The overall goal will be to focus on identifying Model-Derived Subgroups (MDS), which are compact, clinically interpretable patient characterizations defined by small … oncology decision frameworks.” “This collaboration represents an opportunity to apply NetraAI to a rigorously conducted, randomized, precision-oncology dataset and to explore whether explainable, compact patient characterizations can add actionable insight beyond standard analyses,” said Professor Luca Pani, Chief Innovation and Regulatory Office
NETRAMARK UNVEILS AI DRIVEN INSIGHTS FOR MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA AT ISCTM CONFERENCE - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NETRAMARK UNVEILS AI DRIVEN INSIGHTS FOR MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA AT ISCTM CONFERENCE March 6, 2025 | 7 min read Twitter LinkedIn Facebook Email Print TORONTO , March 5, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV)&nbs … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions November 27, 2018 | 3 min read Twitter LinkedIn Facebook Email Print NetraMark Corp. and Juvenescence Ltd. have partnered to form NetraPharma, a joint venture that is us … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NETRAMARK PROVIDES Q3 BUSINESS UPDATE AND HIGHLIGHTS PROGRESS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases NETRAMARK PROVIDES Q3 BUSINESS UPDATE AND HIGHLIGHTS PROGRESS August 20, 2024 | 7 min read Twitter LinkedIn Facebook Email Print TORONTO , Aug. 20, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in … everages a pharmaceutical company's own Phase 1, 2, or 3 clinical trial data to apply proprietary AI that identifies the key subpopulations driving drug response, placebo response, and adverse events. The Company developed its offerings to help address the needs of pharmaceutical and biotechnology companies that need to leverage their investments to improve future clinical trial outcomes. Meaningful accomplishments year to date Commercial-Ready and proprietary AI Platform: Th … s on lung cancer trials in the Exploration of Medicine Journal, where NetraAI's application of genetic data helped define a novel subpopulation for future clinical trials. The future objectives for NetraMark R&D budgets of many pharmaceutical companies are robust and investment capital continues to flow toward the development of new therapies. Adopting new and innovative AI based technologies to increase efficiency is quickly becoming the focus of the industry and creatin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY | Joseph Geraci | 16 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
%PDF-1.7 %���� 1 0 obj >/Metadata 813 0 R/ViewerPreferences 814 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}_s�8��{��;�aΖ�3�䭭��q&{�g26ٳ5�{ ����%_YNN��~��-�R��@��֎��R��F��|�r�|\�� �����Z_5��_|�; v7��������/���vu��/��8�[�w�C�����W�����Y�f��$K��Y� 7Y�V�d�����E���F̣:��iŃR`\�� e��2����L�,�� �#� ��R-��_� u���;~��{�����a�?�� S��#yD��ϑx V��Wq��̒xe�����D� �oUh������[��^��]ܗ��$]P\�%2����7 re��n��~�ʠ�Je5 5ԴtEBT�D�6PyV�y˕�� ��
%PDF-1.3 %��������� 3 0 obj > stream x��˒ G��� �#�R�/[ Xab"X`� 1��lx~�?��*kz$Y -��L��������`����ֺK�/��f�Zͻ7���?:��G��� _s�6g ����a�8x=�8?��̷]�`�\���q^��J�Z �YY ���՟{��_?�����-vl��i�mi~�y�h^��љ���%����ᛟ���͗�?|���㛟}�����]��šȒs1/�oK����{y.�`�_������#��=���=r�53�_���Ds��μ����H���;���7w���O����멯���ɯ�x���;S9�������n��d�p��}V���j+B����V��ds���������f�ҙ���`���ˇ���G�R�������[��[��88����ar8�?Bq��k�3��x�=>ǥ��9A�D�Sb|��8�W ���b&�?fC��V�nl���}��� ��'z�s�M�.�| -�$��Hݠ��ϟ����qd^� ���q��� a �8ɼ �'�?���sF|� O5?�p�!E��!17QT�(���儇'�Ԛ� ̒��K������L�,�� �x�9G�~R�� M��\ �0��( … ���J�kN}iriA����No��A�A u4��O�=j D ���: ԕ(5 @2��*O�85)`��ܘ� M���6l�RFp���J8j~BX8�ߎi��J�9�A���4��sIM�!�&{R����4�����h'4;`S 85l� �z�I=M1���=}�3R�w'� ��S ���u����y�G �֩I��Y�=jсޒ^�$���Hǩ,G9�56R݃��.a8��z���nn��ʻ�j6���� 8�is E!�n VMEA淠��oAJ��cY�q����ަ�y抛�Xz�?1����U�!��K����6n~NGEP(��ަ���i�S*��j�pQ��CEs�#�a��TtQN�QE��(�QE�(��.ER��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��)��(��QE�S� … �՟U���*�t&v�&t .¥Z��b��8,�G����j)k��� x lr���I�� |�����m6Q�ʙ��E�a��P#���ڭ �Rfp�ߚ�1Zrjs��7F���^�qL[|��얥���o�c*�F�:3']�����р�r�iӢ�Y�� ��f�����ۛ��ڽ�v8t��@�q,�K� ���wP1����z^�d�ha�{N��� ��3g^����4 t��ф�7���0�C���. �B�+Jg/�q% �i'�M�\�?J�n� �۩J�����G���,�5�h1�4"n7���v�P��P���4�! �hPK�&KbN���-�O'�|)� H��KKS�k�B֧Z�O���IK�&�� �U�� 3�z9/ת��R{�>Z� 6o2��Vqc��\������J�=�#�D�>� ��#a��|�Y!��ч�Ly�g ��k���SZF��gu�� N�?�(�H��� &ڢ �� ar ���I'7���%�kx�d��UM4:�C�
TSX:AIAI Forum Post | PressRelease-37004804 | New Press Release - NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting | NetraMark Holdings Inc Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details . I Agree × Join today and have your say! It’s FREE! Join Now Sign In Become a member today, It's free! We will not release or res … gn Up Privacy Policy | Disclaimer Please Try Again {{ error }} Send my password Submit Return to Login SUCCESS An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password. Become a member today, It's free! We will not release or resell your information to third parties without your permission. Linking with Facebook: Stockhouse membership requires an email address which must be shared by Facebook. By default, joi … ember! Please enter your password to sign in. Remember me Forgot password? Back Submit By providing my email, I consent to receiving messages from Stockhouse. New Post TSX:AIAI - Post by User NetraMark Holdings Inc << Previous Bullboard Posts (0) ••• PressRelease X View Profile View Bullboard History Post by PressRelease on May 20, 2026 7:00am 9 Views Post# 37004804 New Press Release - NetraMark to Present at the American Society of Clinical Psychophar … ember! Please enter your password to sign in. Remember me Forgot password? Back Submit By providing my email, I consent to receiving messages from Stockhouse. {{ dialogTitle }} × Reject Reason {{ policy.description }} {{reasonError}} Additional Comments {{feedbackError}} {{buttonTitle}} Cancel {{submitMsg}} Interested in these industries and sectors? Receive investor kits and email updates from Stockhouse and directly from these companies. Industrials All None Laser Pho … ember! Please enter your password to sign in. Remember me Forgot password? Back Submit I consent to receiving investment related electronic messages from Stockhouse and the companies selected. I may withdraw my consent at any time. Featured News Links Nine Mile Metals Announces Completion of DDH WD-26-01, Intersecting 129.72 Meters of Visual Mine
NetraMark CEO George Achilleos on TSX listing and AI technology | Toronto Stock Exchange posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
%PDF-1.3 %��������� 3 0 obj > stream x��˒ G���e���H��_�f���`�X8㰈�%����Y�UYӭf����3Y���[�/��/���l�1������2�j�R��w�_�No��d�w�&��z����a?mO��������~�y�������#;/� 3�Z�㼛V�/�z�经������?�O �cǪ��J��|��e�wӛ� ��(�Y��/w�?~~����>����������vfv�j�ŢȜR�^g������m�O���g�͢���M�H��u��i��t����u�ο�������t��@����L�L�ߴS������۳��i{laÁ�77����跜,�C��#~���H僳�n�4��v�ė�y�i�߆�b�_�F�C�̧���j�C�7:�G���ۧ�t�����u�f�]�!�b��eh�_�L�����K~� �������/�)uv�r��3�=���9� #^�\����k����� }���vje�IO���iKI��s�N�S�e����`@��sv� ���Z��"1r���G.��ْt���v:��}�����@��1y�P9M�F 0L/��T�\}b�����P���h>1F��RB#���T
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
NetraMark Announces Partnership with Pentara to Detect --> Accessibility: Skip TopNav NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity July 30, 2025 07:11 ET | Source: NetraMark Holdings Inc. NetraMark Holdings Inc. TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data anal
%PDF-1.5 %���� 57 0 obj >stream q endstream endobj 58 0 obj >stream x��=�r�6���?��> �,����J�-�Y�Y'�خԩd &�4i�hFN����q� R4�$�xЍ�w`N�� ���a��7�����j�q�������濧�?�mNX]nw���vw����>z}{{�ܟ�-^� )�tW��o�>�yɲ�.����W0� ��`�W �ρY����Wo�� ����K�����&A��� �S,4�. �a˻�*�s�(�ɍ Bw�Є +$���U^�֬4�@�ˡywR";�K��� ~$�0�0x�g�- �+��^�K�7���=� v�x�����4� �|,풓a��Y|.��8�Y�����E�Hz���9z��#��w�ى\O�r��6�������������D. �W�I� p�xe��Ż2M�-�>-�i/=��� ݅_��5H�Yq �>w��؆G#Z�vM��\� І�� 1��ۢ ]�$mu��DWY �-H:�� +J�ܺ҈ґ���XK�%�-A �{�64�p5|�������)= x�'��m�؛ b���ܾ�+��̙J�� �����R�D�#Ė@��ϖ�r���ȼ�K� … 5 2023-09-11T16:11:40-07:00 2023-09-11T16:11:41-07:00 2023-09-11T16:11:41-07:00 application/pdf endstream endobj 190 0 obj >/App >/PubSec >>>/M (D:20230911161141-07'00')/Reason (Digitally verifiable PDF exported from www.docusign.com)/ByteRange[0 0000478526 0000544062 0000009418]/Contents /Reference[ >/TransformMethod/FieldMDP>>]>> endobj 189 0 obj >>>/BBox[0 0 0 0]/Matrix[1.0 0 0 1.0 0 0]/Length 9>>stream /n2 Do endstream endobj 193 0 obj >/BBox[0 0 0 0]/Length 19>>stream /T … �#��c(���N~�A� ;8 ���%�xg�"�3�A���\R�����(��,}6��1�uഓ7���:��܍����'�RFP`�3__F��`r�K �����ؤ��YW��5�EA\2��%r_@)n��e}�r��P���g��h_;a�2�^�(ތ��.�����:�=�)� N�-M�b�w,�Wȼ�rż�!�J�'�7i+��i�qa�.�-�g��#(uX㕿{�����4U�;�~ ���2���[�d��� �z4���F�*���!�vH������� 6 ~����z���p��26����G暫�I�i~i i��!c��?B3v��DY �X�iNt��� .��4JU�5T!Ei�,�8ȝ�3�Cf�� ��>� v� E��.|�J=��O}F�XEo��]ڄ���#���W� ��N��1� [�{�s+�C8h.�Ix�psr�y�L�Q�Q8����>��U.� g~م�we՜�� … 5 2023-09-11T16:11:40-07:00 2023-09-11T16:11:41-07:00 2023-09-11T16:11:41-07:00 application/pdf endstream endobj 235 0 obj >stream x�}PMo�0 �+��5��E'��&�41&T�i4r�N�;�ߓf�vz~/���Y*@`i��&�@�VIcN| lR�x�/A��$[X�Į��?����.4��P�Շ�+d����0���\���p��i�0ό,�$"C�� � q�����Aw�z�� ~����8�/94B+|�k��Y�z�y�=5J�+҆*W5�ko�$��F�B������)/JK��|�iv>Av���c�5� ��3 ��p�\D endstream endobj 248 0 obj >stream x�c��@���Q� �02pj��L@�*�� Y��`�1X` 6��`�1�AV�B �(� e�d@ LP�T�C� ��N ends
NetraMark Holdings Inc. (AINM.F) Leadership & Management Team Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION NetraMark Holdings Inc. OTCPK:AINM.F Stock Report Market Cap: US$40.6m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding … Company Overview 1 Valuation 2 Future Growth 3 Past Performance 4 Financial Health 5 Dividend 6 Management 7 Ownership Other Information Stock Community View Dividend NetraMark Holdings Management Management criteria checks 4/4 NetraMark Holdings' CEO is George Ach … ence Guy is currently a Managing Director with Next Edge Capital, an investment fund manager, where he focuses on strategic partnerships, corporate initiatives, and the evaluation of new investment opportunities. He brings extensive experience in financial leadership, fund management, and corporate development across both private and public markets. Prior to Next Edge Capital, Lawrence Guy served as a Vice President at Purpose Investments, where he joined the firm at an early … ence Guy is currently a Managing Director with Next Edge Capital, an investment fund manager, where he focuses on strategic partnerships, corporate initiatives, and the evaluation of new investment opportunities. He brings extensive experience in financial leadership, fund management, and corporate development across both private and public markets. Prior to Next Edge Capital, Lawrence Guy served as a Vice President at Purpose Investments, where he joined the firm at an early … traAI--NetraMark's explainable AI/ML platform--and discussed its potential application as an enrichment methodology in clinical trial design. During the discussion, FDA suggested that NetraMark consider exploring the Agency's Model-Informed Drug Development (MIDD) Paired Meeting Program as a potential avenue for further regulatory dialogue. CPIM discussions are non-regulatory, drug product-independent, and non-binding on both FDA and CPIM requesters. The CPIM held b … can improve clinical trial success rates. Through this offering, NetraMark will apply NetraAI to customers' clinical trial data and seek to identify key variables that drive specific trial outcomes, provide testable hypotheses about the role that these variables play in patient responses and recommend inclusion and exclusion criteria based o
%PDF-1.7 %���� 1 0 obj >/Metadata 380 0 R/ViewerPreferences 381 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 3240 3240] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[sܸ���?�e����=@`v>Uɒ�q"_by�I��C[��δ.�%�8��s��$�j�)o*c5I\����s�q��v�iq|[ �?����T���tVM���{R��t�&�����ܷ�_���O��l Zm˹�=��٨}��?����4��{*��L��,�N�����t�ә�o�����J1Y�\M��������bU B5��Z�&\�=jF��� ��ޙ�k(d����T�ֱَ#���z����θ�Q͵*��ͼ�!��jy� ��b�~Z5����������f!ei�R@��i POKmQ���Ж?�ɋږ��GΦj�kUV� vN���`�L�V�\��^�v�f*��_��
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/ExtGState >/Font >/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 5 0 obj >stream H��V�n�8}�W��**�w�@Q�9qח�Q�F ���f�Ļ��n�~g(R�e[͋I��9�3g��������ݎ|���w���_�{����n�L����?�2��B���\� ��hF�f�n~|���gC��v�ۼ�����ǧ���i�B>~ ��$TI^U�pR=$�QW��X�)��+ *��� I����J��� �Q#�v�0Xr�I �r�~�̆�x `��$&$��H�qj�(tv��GO�d�����K-�w,�/�.;So�տ�5o��o�-�l�,�p�My�7>C����҆&=�����#��u �\;}E�m+���b�X3P(�� ��D w�{3 Y�拔�^�f��8���� �6� (��H�w+�[�6�rǃ�b�F������~�O�j�Y �(�+�j�f ��QKzW� ��ADn"N~� p&���u>:ƽ� … '���m�F��ž���]h���Kl���d���k�߿�ۜ�!I-yw=�zچC���K�m� > endobj 255 0 obj >stream application/postscript Print Kevin Mitchell 2022-01-08T13:02:31-07:00 2022-01-08T13:02:31-07:00 2022-01-08T13:02:30-07:00 Adobe Illustrator 26.0 (Windows) xmp.iid:19c738cd-2847-f14a-9dd5-c24ade646c33 xmp.did:19c738cd-2847-f14a-9dd5-c24ade646c33 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:6314beea-5303-9e45-b154-d72b928e7b2a xmp.did:6314beea-5303-9e45-b154-d72b928e7b2a uuid:5D20892493BF … 2019-06-24T15:20:57-06:00 Adobe Illustrator CC 23.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:19c738cd-2847-f14a-9dd5-c24ade646c33 2022-01-08T13:02:31-07:00 Adobe Illustrator 26.0 (Windows) / Print False False 1 2.235663 0.913141 Inches PANTONE 343 C Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 CMYK Red CMYK PROCESS 0.000000 100
Podcasts | NetraMark AI Solutions TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact Podcasts AI for Pharma Growth: The Economics of Clinical Trials and the Relationship to AI Mar 4, 2026 Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr. Andree Bates is joined by Dr. Joseph Geraci of NetraMark to b
NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Galler … ptimization of clinical trials by uncovering hidden patient subpopulations, the application of NetraMark's AI technology in Phase 2 and select Phase 3 clinical trials, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, Worldwide's ability to accelerate development timelines, refine patient stratification, reduce placebo response variability, and enhance overall trial power, the potential for NetraMark's partnership with Worldwide to r … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
NetraMark Holdings (OTCPK:AINM.F) - Stock Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION Stocks / Healthcare Updated 1h ago NetraMark Holdings Inc. OTCPK:AINM.F Stock Report Market Cap US$40.6m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding Watch Watching … Updated 1h ago Data from Company Financials & 1 Analyst Share Price n/a 1Y -57.9% 7D -25.6% 1D -4.3% Portfolio Value View Data from Company Financials & 1 Analyst NetraMark Holdings Inc. OTCPK:AINM.F Stock Report Market Cap: US$40.6m P … ence Guy is currently a Managing Director with Next Edge Capital, an investment fund manager, where he focuses on strategic partnerships, corporate initiatives, and the evaluation of new investment opportunities. He brings extensive experience in financial leadership, fund management, and corporate development across both private and public markets. Prior to Next Edge Capital, Lawrence Guy served as a Vice President at Purpose Investments, where he joined the firm at an early … traAI--NetraMark's explainable AI/ML platform--and discussed its potential application as an enrichment methodology in clinical trial design. During the discussion, FDA suggested that NetraMark consider exploring the Agency's Model-Informed Drug Development (MIDD) Paired Meeting Program as a potential avenue for further regulatory dialogue. CPIM discussions are non-regulatory, drug product-independent, and non-binding on both FDA and CPIM requesters. The CPIM held b … can improve clinical trial success rates. Through this offering, NetraMark will apply NetraAI to customers' clinical trial data and seek to identify key variables that drive specific trial outcomes, provide testable hypotheses about the role that these variables play in patient responses and recommend inclusion and exclusion criteria based on these insights that can potentially be used to improve the success of future clinical trials. Customers participating in the offer
Leveraging Large Language Models with NetraAI for Clinical Trial De-Risking: Launching NetraGPT - Netramark TSX: AIAI | OTCQB : AINMF | FRA: PF0 About About Careers Solutions NetraAI Evidence Blog Podcasts Posters Publications White Papers Investors & Media Events Filings Investors Overview Press Releases Stock Information Contact May 22, 2023 Leveraging Large Language Models with NetraAI for Clinical Trial De-Risking: Launching NetraGPT NetraAI represents a distinctive, Good Clinical Practice (GCP)-authenticated machine learning architecture that offers an accessible interface for resear … mprehensible report that a field expert can carefully review. NetraGPT’s Application in Oncology Cancer comprises a complex and heterogeneous assortment of disorders, each involving a range of molecular mechanisms. NetraAI’s divide-and-conquer strategy, coupled with its foundation in systems biology, facilitates a more profound comprehension of the driving forces underlying the diverse manifestations of these diseases. For instance, glioma (a form of brain cancer